日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies

基于既往对高级疗法反应不足或不耐受的Risankizumab疗效和安全性：INSPIRE和COMMAND 3期研究的事后分析

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjaf005
Panaccione, Remo; Louis, Edouard; Colombel, Jean-Frederic; D'Haens, Geert; Peyrin-Biroulet, Laurent; Dubinsky, Marla; Takeuchi, Ken; Rubin, David T; Kalabic, Jasmina; Chien, Karen B; Chen, Su; Cheng, Ling; Zhang, Yafei; Duan, W Rachel; Vladea, Ramona; Hecht, Patrick M; Morisset, Pierre; Schreiber, Stefan; Ferrante, Marc
多发性骨髓瘤
发表日期：2025
文献求助 收藏

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

利沙珠单抗在治疗中重度活动性溃疡性结肠炎患者中的疗效和安全性：减少皮质类固醇用量的作用

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjaf025
Reinisch, Walter; Loftus, Edward V Jr; Schreiber, Stefan; Rubin, David T; Louis, Edouard; Hecht, Patrick M; Barrachina, Elena Marced; Kalabic, Jasmina; Vladea, Ramona; Sharma, Dolly; Duan, Weijiang Rachel; Zhang, Yafei; Panaccione, Remo
结肠炎
肠炎
发表日期：2025
文献求助 收藏

Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies

Risankizumab治疗溃疡性结肠炎患者可缓解症状并显著改善生活质量：随机INSPIRE和COMMAND研究的事后分析

期刊:American Journal of Gastroenterology
影响因子:7.6
doi:10.14309/ajg.0000000000003420
Torres, Joana; Panés, Julian; Siegel, Corey A; Dubinsky, Marla C; Dulai, Parambir S; Tanida, Satoshi; Danese, Silvio; Kalabic, Jasmina; Lai, Jyun-Heng; Shukla, Nidhi; Rizzo, Leah; Holweg, Cecile; Sharma, Dolly; Panaccione, Remo
结肠炎
肠炎
多发性骨髓瘤
发表日期：2025
文献求助 收藏

Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

评估 Risankizumab 对中度至重度活动性溃疡性结肠炎或克罗恩病患者细胞色素 P450 底物药代动力学的影响

期刊:Clinical Pharmacokinetics
影响因子:4.6
doi:10.1007/s40262-024-01462-4
Ronilda D'Cunha, Tofial Azam, Jasmina Kalabic, Toni Anschutz, Adi Lahat, Yinuo Pang
免疫
细胞生物学
肠炎
其它细胞
发表日期：2025
文献求助 收藏

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

巴西一项随机、双盲、3期临床试验（含开放标签扩展期）结果显示，risankizumab 与甲氨蝶呤治疗中重度斑块状银屑病患者的疗效和安全性存在差异。

期刊:Anais Brasileiros De Dermatologia
影响因子:3.6
doi:10.1016/j.abd.2024.08.002
Cestari, Tania F; Souza, Cacilda da Silva; Azulay-Abulafia, Luna; Romiti, Ricardo; Carvalho, André V E; Silva de Castro, Caio César; Marques, Sílvio Alencar; Antonio, João Roberto; Fabrício, Lincoln; Soliman, Ahmed M; Wu, Tianshuang; Sinvhal, Ranjeeta; Stakias, Vassilis; Song, Alexandra P; Kalabic, Jasmina; Martin, Naomi; Oyafuso, Luiza Keiko Matsuka
银屑病
发表日期：2025
文献求助 收藏

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's Disease

利沙珠单抗治疗后早期内镜检查结果与克罗恩病患者住院和手术次数减少相关

期刊:Gastro Hep Advances
影响因子:
doi:10.1016/j.gastha.2024.08.022
Feagan, Brian G; Colombel, Jean-Frederic; Panaccione, Remo; Schreiber, Stefan; Ferrante, Marc; Kamikozuru, Koji; Ma, Christopher; Lee, Wan-Ju; Griffith, Jenny; Joshi, Namita; Kligys, Kristina; Kalabic, Jasmina; Xuan, Si; Dubinsky, Marla
克罗恩病
发表日期：2025
文献求助 收藏

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease

利沙珠单抗诱导和维持治疗对克罗恩病患者住院率的影响

期刊:Gastro Hep Advances
影响因子:
doi:10.1016/j.gastha.2024.100603
Feagan, Brian G; Panaccione, Remo; Schreiber, Stefan; Loftus, Edward V Jr; Peyrin-Biroulet, Laurent; Arai, Takehiro; Lee, Wan-Ju; Griffith, Jenny; Kalabic, Jasmina; Kligys, Kristina; Xuan, Si; Liao, Xiaomei; Ferrante, Marc
克罗恩病
发表日期：2025
文献求助 收藏

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.

Risankizumab治疗溃疡性结肠炎：两项随机临床试验

期刊:Journal of the American Medical Association
影响因子:55
doi:10.1001/jama.2024.12414
Louis Edouard, Schreiber Stefan, Panaccione Remo, Bossuyt Peter, Biedermann Luc, Colombel Jean-Frederic, Parkes Gareth, Peyrin-Biroulet Laurent, D'Haens Geert, Hisamatsu Tadakazu, Siegmund Britta, Wu Kaichun, Boland Brigid S, Melmed Gil Y, Armuzzi Alessandro, Levine Phillip, Kalabic Jasmina, Chen Su, Cheng Ling, Shu Lei, Duan W Rachel, Pivorunas Valerie, Sanchez Gonzalez Yuri, D'Cunha Ronilda, Neimark Ezequiel, Wallace Kori, Atreya Raja, Ferrante Marc, Loftus Edward V Jr
炎症/感染
肠炎
炎症
发表日期：2024
文献求助 收藏

Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies

Risankizumab诱导治疗可早期改善克罗恩病患者的症状，且这些症状与未来的临床和内镜结果相关：ADVANCE、MOTIVATE和FORTIFY 3期研究的事后分析

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjad206
Colombel, Jean-Frederic; Schreiber, Stefan; D'Haens, Geert; Rizzo, Joanne; Kligys, Kristina; Griffith, Jenny; Zambrano, Javier; Zhou, Qian; Zhang, Yafei; Kalabic, Jasmina; Rieder, Florian; Dubinsky, Marla C; Panaccione, Remo
克罗恩病
发表日期：2024
文献求助 收藏

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial

在一项随机3期试验中，Risankizumab维持治疗可维持克罗恩病患者的诱导反应。

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjad168
Ferrante, Marc; Irving, Peter M; Abreu, Maria T; Axler, Jeffrey; Gao, Xiang; Cao, Qian; Fujii, Toshimitsu; Rausch, Astrid; Torres, Joana; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; Kligys, Kristina; Berg, Sofie; Liao, Xiaomei; Zhou, Qing; Kalabic, Jasmina; Feagan, Brian; Panaccione, Remo
克罗恩病
发表日期：2024
文献求助 收藏